Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) is anticipated to post its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect Barinthus Biotherapeutics to post earnings of ($0.27) per share and revenue of $0.22 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 12:30 PM ET.
Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) last released its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02. On average, analysts expect Barinthus Biotherapeutics to post ($0.93) EPS for the current fiscal year and ($1.07) EPS for the next fiscal year.
Barinthus Biotherapeutics Price Performance
Shares of Barinthus Biotherapeutics stock opened at $0.74 on Wednesday. Barinthus Biotherapeutics has a 1 year low of $0.51 and a 1 year high of $1.83. The firm has a market cap of $30.23 million, a price-to-earnings ratio of -0.72 and a beta of -0.37. The company has a 50-day moving average of $0.74 and a 200 day moving average of $0.66.
Analysts Set New Price Targets
A number of equities analysts have weighed in on the stock. Zacks Research raised shares of Barinthus Biotherapeutics to a “hold” rating in a research note on Wednesday, August 26th. Weiss Ratings cut Barinthus Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $4.00.
Check Out Our Latest Stock Analysis on Barinthus Biotherapeutics
Barinthus Biotherapeutics Company Profile
Barinthus Biotherapeutics plc is a clinical-stage biotechnology company developing T-cell immunotherapies designed to treat autoimmune diseases, chronic infections and cancer. The company’s approach is intended to direct or regulate immune responses with greater specificity, with the goal of restoring immune tolerance or strengthening disease-fighting T-cell activity.
Barinthus’ product pipeline includes VTP-1000, an investigational antigen-specific therapy being developed for celiac disease, and VTP-300, a therapeutic vaccine candidate aimed at chronic hepatitis B infection.
See Also
- Five stocks we like better than Barinthus Biotherapeutics
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
Receive News & Ratings for Barinthus Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barinthus Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
